Marion de Jong

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 468 citations

Clinical Translation, Medicine, Pathology +2

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

Roelf Valkema, Marion de Jong, Willem H. Bakker et al. · Seminars in Nuclear Medicine · 2002 · 430 citations

Medicine, Radionuclide Therapy, Peptide Library +8

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

E. P. Krenning, WH Bakker, P P Kooij et al. · PubMed · 1992 · 422 citations

Engineering, Pathology, Positron Emission Tomography +18

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 418 citations · Full text

Surgical Oncology, Pancreatic Cancer, Medicine +6

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Roelf Valkema, Stanislas Pauwels, Larry K. Kvols et al. · PubMed · 2005 · 334 citations